Back to Press-Releases
DIA 2014 50th Annual Meeting to Highlight New IMI Collaborative Initiative
GetReal project seeks practical solutions for integrating real-world data to better inform the drug development process
GetReal, a collaborative project recently launched by the European Union’s Innovative Medicines Initiative (IMI), will be highlighted at the DIA 2014 50th Annual Meeting taking place June 15 to 19 at the San Diego Convention Center. The forum discussion—How Can Studies That Inform Relative Effectiveness Best Be Incorporated Into Global Drug Development Plans?—will be held June 19 at 10:45 a.m.
As Europe’s largest public-private partnership, IMI seeks to create better and safer medicines for patients by supporting more effective discovery of information in the drug development process. The GetReal project connects health technology assessment agencies, industry and regulatory bodies with academia, subject matter and patient group experts to enhance this discovery process by better understanding how real-world data and analytical techniques can inform and improve drug development.
“Our annual meeting is a global platform to facilitate innovation that will change the future of health care,” said Barbara L. Kunz, DIA global chief executive. “The GetReal project exemplifies the collaboration needed to bring safer and better products to patients around the world.”
GetReal, a collaborative project recently launched by the European Union’s Innovative Medicines Initiative (IMI), will be highlighted at the DIA 2014 50th Annual Meeting taking place June 15 to 19 at the San Diego Convention Center. The forum discussion—How Can Studies That Inform Relative Effectiveness Best Be Incorporated Into Global Drug Development Plans?—will be held June 19 at 10:45 a.m.
As Europe’s largest public-private partnership, IMI seeks to create better and safer medicines for patients by supporting more effective discovery of information in the drug development process. The GetReal project connects health technology assessment agencies, industry and regulatory bodies with academia, subject matter and patient group experts to enhance this discovery process by better understanding how real-world data and analytical techniques can inform and improve drug development.
“Our annual meeting is a global platform to facilitate innovation that will change the future of health care,” said Barbara L. Kunz, DIA global chief executive. “The GetReal project exemplifies the collaboration needed to bring safer and better products to patients around the world.”
Incorporating data from real-world clinical settings into drug development and associated decision-making represents a serious challenge for pharmaceutical companies, regulators and health authorities; the GetReal project unites these key stakeholders to develop new approaches and greater consensus. The DIA forum will focus specifically on the challenges in implementing alternative drug development strategies prior to medicine authorization, and explain how global drug development plans can better incorporate relative effectiveness objectives, real-world data and analytical techniques prior to this authorization.
Contact: Tiffany Cohen
+1.202.499.4411
tcohen@reingold.com
###